Cytokinetics, Inc. : Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance

  Cytokinetics, Inc. : Cytokinetics, Incorporated Receives NASDAQ Notice of
                         Minimum Bid Price Compliance

South San Francisco, CA, January 25, 2013 - Cytokinetics, Incorporated
(NASDAQ: CYTK), announced today that it has received a notice from The Nasdaq
Stock Market ("Nasdaq") confirming that for the last 10 consecutive business
days, the closing bid price of the Company's common stock has been at $1.00
per share or greater. Accordingly, the Company has regained compliance with
the minimum $1.00 bid price per share requirement.

As previously reported, the  Company received notice from  Nasdaq on June  18, 
2012 that the  Company's common  stock had failed  to maintain  a minimum  bid 
price of $1.00 over the previous  30 consecutive business days as required  by 
the Listing  Rules of  The Nasdaq  Stock Market.  On December  18, 2012,  the 
Company transferred  its  listing to  the  Nasdaq Capital  Market  and  Nasdaq 
provided the  Company until  June  17, 2013  to  achieve compliance  with  the 
minimum $1.00 bid price per share requirement.

Nasdaq has informed the Company that this matter is now closed.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv, a skeletal muscle  activator, as a potential  treatment 
for  diseases  and  conditions  associated  with  aging,  muscle  wasting   or 
neuromuscular dysfunction. Tirasemtiv is currently  the subject of a Phase  II 
clinical trials program and has been granted orphan drug designation and  fast 
track status by  the U.S. Food  and Drug Administration  and orphan  medicinal 
product designation  by  the  European  Medicines  Agency  for  the  potential 
treatment  of  amyotrophic  lateral  sclerosis,  a  debilitating  disease   of 
neuromuscular  impairment  in   which  treatment   with  tirasemtiv   produced 
potentially clinically relevant  pharmacodynamic effects in  Phase II  trials. 
All of these  drug candidates  have arisen from  Cytokinetics' muscle  biology 
focused research activities  and are  directed towards  the cytoskeleton.  The 
cytoskeleton is a complex biological  infrastructure that plays a  fundamental 
role within every human cell. Additional information about Cytokinetics can be
obtained at

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to the properties and potential benefits of  Cytokinetics' 
drug candidates and potential  drug candidates. Such  statements are based  on 
management's current expectations,  but actual results  may differ  materially 
due to  various  risks  and  uncertainties, including,  but  not  limited  to, 
potential difficulties  or  delays  in the  development,  testing,  regulatory 
approval and production  of Cytokinetics' drug  candidates and potential  drug 
candidates  that  could  slow  or  prevent  clinical  development  or  product 
approval, including risks that current and past results of clinical trials  or 
preclinical studies may not  be indicative of  future clinical trials  results 
and that Cytokinetics' drug candidates and potential drug candidates may  have 
unexpected adverse  side  effects  or  inadequate  therapeutic  efficacy.  For 
further information regarding these and  other risks related to  Cytokinetics' 
business, investors should consult  Cytokinetics' filings with the  Securities 
and Exchange Commission.

Jodi L. Goldstein
Manager, Marketing & Corporate Communications
(650) 624-3000


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.